Mar 13 |
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
|
Mar 7 |
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
|
Mar 4 |
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
|
Feb 22 |
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
|
Feb 17 |
Insider Stock Buying Reaches US$3.06m On Fortress Biotech
|
Feb 13 |
Fortress Biotech, Inc. 9.375% CUM RED PER PREF SER A USD25.00 goes ex dividend tomorrow
|
Feb 2 |
Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries
|
Jan 11 |
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
|
Jan 11 |
Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference
|
Jan 11 |
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
|